Circulating endothelial cell (CEC) as a diagnostic and prognostic marker in malignant pleural mesothelioma (MPM)

Annals of Surgical Oncology

Volumn 19, Issue 13, 2012, Pages 4229-4237

  Yoneda, Kazue ^a   Tanaka, Fumihiro ^a,b   Kondo, Nobuyuki ^a   Orui, Hayato ^a   Hashimoto, Masaki ^a   Takuwa, Teruhisa ^a   Matsumoto, Seiji ^a   Okumura, Yoshitomo ^a,c   Tsubota, Noriaki ^a   Sato, Ayuko ^a   Tsujimura, Tohru ^a   Kuribayashi, Kozo ^a   Fukuoka, Kazuya ^a   Nakano, Takashi ^a   Hasegawa, Seiki ^a  

^a HYOGO COLLEGE OF MEDICINE   (Japan)

^b UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

^c Itami City Hospital   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; CD146 ANTIBODY; UNCLASSIFIED DRUG;

AGED; ANGIOGENESIS; AREA UNDER THE CURVE; ARTICLE; AUTOMATION; BLOOD SAMPLING; CANCER PROGNOSIS; CELL COUNT; CIRCULATING ENDOTHELIAL CELL; CONFIDENCE INTERVAL; CONTROLLED STUDY; CORRELATION COEFFICIENT; DISEASE MARKER; ENDOTHELIUM CELL; FEMALE; HAZARD RATIO; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; OVERALL SURVIVAL; PLEURA MESOTHELIOMA; PROSPECTIVE STUDY; RECEIVER OPERATING CHARACTERISTIC;

ADULT; AGED; AGED, 80 AND OVER; AREA UNDER CURVE; CASE-CONTROL STUDIES; ENDOTHELIAL CELLS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MESOTHELIOMA; MIDDLE AGED; NEOPLASM STAGING; NEOPLASTIC CELLS, CIRCULATING; NEOVASCULARIZATION, PATHOLOGIC; PLEURAL NEOPLASMS; PROGNOSIS; PROSPECTIVE STUDIES; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 84876498218     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-012-2506-0     Document Type: Article

References (30)

1. Ismail-Khan R, Robinson LA, Williams CC, Garrett CR, Bepler G, Siomn G. Malignant pleural mesothelioma: a comprehensive review. Cancer Control. 2006;13:255-63. (Pubitemid 44600936)
2. Tsiouris A, Walesby RK. Malignant pleural mesothelioma: current concept in treatment. Nat Clin Practice Oncol. 2007;4:3 44-52.
3. Scherpereel A, Astoul P, Baas P, Berghmans T, Clayson H, de Vuyst P, et al. Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma. Eur Respir J. 2010;35:479-95.
4. Stahel RA, WeDer W, Lievens Y, Felip E. Malignant pleural mesothelioma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010;21:v126-8.
5. Van Der Bij S, Schaake E, Koffijberg H, Burgers JA, de Mol BAJM, Moons KGM. Markers for the non-invasive diagnosis of mesothe-lioma: a systematic review. Br J Cancer. 2011;104:1325-33.
6. Lee AY, Raz DJ, He B, Jablons DM. Update on the molecular biology of malignant pleural mesothelioma. Cancer. 2007;109: 1454-61. (Pubitemid 46595678)
7. Sculier JP, Berghmans T, Meert AP. Update in lung cancer and mesothelioma. Am J Respir Crit Care Med. 2010;181:773-81.
8. Cao CQ, Yan TD, Bannon PG, McCaughan BC. A systemic review of extrapleural pneumonectomy for malignant pleural mesothelioma. J Thorac Oncol. 2010;5:1692-703.
9. Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol. 2003;21:2636-44. (Pubitemid 46606305)
10. Ray M, Kindler HL. Malignant pleural mesothelioma: an update on biomarkers and treatment. Chest. 2009;136:888-96.
11. Folkman J. Anti-angiogenesis: new concept for therapy of solid tumors. Ann Surg. 1972;175:409-16.
12. Yano S, Li Q, Wang W, Yamada T, Takeuchi S, Nakataki E, et al. Antiangiogenic therapies for malignant pleural mesotheli-oma. Front Biosci. 2011;16:740-8.
13. Ohta Y, Shridhar Y, Bright RK, Kalemkerian GP, Du W, Carbone M, et al. VEGF and VEGF type C play an important role in angiogenesis and lymphangiogenesis in human malignant meso-thelioma tumours. Br J Cancer. 1999;81:54-61. (Pubitemid 29415491)
14. Kumar-Singh S, Weyler J, Martin MJ, Vermeulen PB, E. Van Marck. Angiogenic cytokines in mesothelioma: a study of VEGF, FGF-1 and-2, and TGF beta expression. J Pathol. 1999;189: 72-8. (Pubitemid 29406822)
15. Tolnay E, Kuhnen C, Wiethege T, König JE, Voss B, Müller KM. Hepatocyte growth factor/scatter factor and its receptor c-Met are overexpressed and associated with an increased microvessel density in malignant pleural mesothelioma. J Cancer Res Clin Oncol. 1998;124:291-6. (Pubitemid 28332909)
16. Monestiroli S, Mancuso P, Burlini A, Pruneri G, Dell'Agnola C, Gobbi A, et al. Kinetics and viability of circulating endothelial cells as surrogate of angiogenesis marker in an animal model of human lymphoma. Cancer Res. 2001;61:4341-4. (Pubitemid 32685756)
17. Mancuso P, Rabascio C, Bertolini. Strategies to investigate circulating endothelial cells in cancer. Pathophysiol Haemost Thromb. 2004;33:503-6.
18. Strijbos MH, Gratama JW, Kraan J, Lamers CH, den Bakker, Sleijfer S. Circulating endothelial cells in oncology: pitfalls and promises. Br J Cancer. 2008;98:1731-5. (Pubitemid 351748848)
19. Beerepoot LV, Mehra N, Vermaat JSP, Zonnenberg BA, Gebbink MFGB, Voest EE. Increased levels of viable circulating endo-thelial cells are an indicator of progressive disease in cancer patients. Ann Oncol. 2004;15:139-45. (Pubitemid 38139616)
20. Kawaishi M, Fujiwara Y, Fukui T, et al. Circulating endothelial cells in non-small cell lung cancer patients treated with carbo-platin and paclitaxel. J Thorac Oncol. 2009; 4:208-13.
21. Rowand JL, Martin G, Doyle GV, Miller MC, Pierce MS, Connelly MC, et al. Endothelial cells in peripheral blood of healthy subjects and patients with metastatic carcinomas. Cytometry Part A. 2007;71A:105-13. (Pubitemid 46238939)
22. Rusch VW. A proposed new international TNM staging system for malignant pleural mesothelioma from the international mesothelioma interest group. Lung Cancer. 1996;14:1-12.
23. Lyden D, Hattori K, Dias S, Costa C, Blaikie P, Butros L, et al. Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth. Nat Med. 2001;7:1194-201. (Pubitemid 33063774)
24. Peters BA, Diaz LA, Polyak K, Meszler L, Romans K, Guinan EC, et al. Contribution of bone-marrow-derived endothelial cells to human tumor vasculature. Nat Med. 2005;11:261-2. (Pubitemid 40460552)
25. Ronzoni M, Manzoni M, Mariucci S, Loupakis F, Brugnatelli S, Bencardino K, et al. Circulating endothelial cells and endothelial progenitors as predictive markers of clinical response to bev-acizumab-based first-line treatment in advanced colorectal cancer patients. Ann Oncol. 2010;21:2382-9.
26. Allard WJ, Matera J, Miller MC, Repollet M, Connelly MC, Rao C, et al. Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy or patients with nonmalignant diseases. Clin Cancer Res. 2004;10:6897-904. (Pubitemid 39383039)
27. Tanaka F, Yoneda K, Kondo N, Hashimoto M, Takuwa T, Matsumoto S, et al. Circulating tumor cell as a diagnostic marker in primary lung cancer. Clin Cancer Res. 2009;15:6980-6.
28. Alix-Panabières, C, Riethdorf S, Pantel K. Circulating tumor cells and bone marrow micrometastasis. Clin Cancer Res. 2008;14: 5013-21.
29. Curren D, Sahmound T, Therasse P, Van Meerbeeck J, Postmus PE, Giaccone G. Prognostic factors in patients with pleural mesothelioma: the European Organization for Research and Treatment of cancer experience. J Clin Oncol. 1998;16:145-52. (Pubitemid 28041592)
30. Fennell DA, Parmer A, Shamash J, Evans MT, Sheaff MT, Sylvester R, et al. Statistical validation of the EORTC prognostic model for malignant pleural mesothelioma based on three consecutive phase II studies. J Clin Oncol. 2005;23:184-9. (Pubitemid 41702637)